Skip to main content

Advertisement

Log in

Tolerability and persistence in a large, prospective case series of women prescribed mirabegron

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Most published data on mirabegron relates to short-term clinical trials and suggest that it might be effective in controlling OAB and have low side effects. This study aimed to identify persistence with mirabegron, changes in symptoms and quality of life, and predictors of perseverance over 1 year.

Methods

The study was a large, prospective case series of 354 patients who were prescribed mirabegron for OAB between February 2013 and July 2014. At 1 year, patients filled out patient global impression of improvement, the International Consultation on Incontinence female lower urinary tract symptoms questionnaire (ICIQ-FLUTS) and PFDI questionnaires. The reasons for discontinuing treatment were identified.

Results

Outcomes were available for 88 % of the cohort. Twenty five percent continued mirabegron therapy at 1 year with 26 % “very much better” and 37 % “much better”. ICIQ-FLUTS (17.2–13.4; p = 0.002) and urinary distress inventory (UDI) (59.2–44.3; p < 0.001) scores demonstrated significant improvements from baseline (pre-treatment) compared with 1 year. The ICIQ-FLUTS “filling score” increased from 3.55 at 6 weeks to 5.27 at 1 year (p = 0.02) despite continuing mirabegron therapy. The most common causes of discontinuation were lack of efficacy (26 %) and side effects (10 %). Thirty-seven percent of the cohort was taking mirabegron in combination with an anticholinergic. Patients who were treatment naïve were more likely to discontinue mirabegron than those who had previously taken anticholinergics (p = 0.02).

Conclusions

Over two thirds of patients discontinue mirabegron therapy within 1 year. A significant proportion of patients were on combined therapy to control symptoms. The initial improvement in symptom scores seems to deteriorate. The improvements in quality of life are sustained in patients who persist with therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68 [2 Suppl]:38–48

    Article  PubMed  Google Scholar 

  2. Veenboer PW, Bosch JL (2014) Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 191(4):1003–1008

    Article  CAS  PubMed  Google Scholar 

  3. Maman K, Aballea S, Nazir J et al (2014) Comparative efficacy and safety of medical treatments for the management of overactive bladder; a systematic literature review and mixed treatment comparison. Eur Urol 65:755–765

    Article  CAS  PubMed  Google Scholar 

  4. Duckett JR, Vella M, Kabalakuntia G, Basu M (2007) Tolerability and efficacy of duloxetine in a nontrial situation. BJOG 114(5):543–547

    Article  CAS  PubMed  Google Scholar 

  5. Chapple CR, Kaplan SA, Mitcheson D et al (2014) Mirabegron 50mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol 21:960–967

    Article  CAS  PubMed  Google Scholar 

  6. Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 65:309–314

    Article  CAS  PubMed  Google Scholar 

  7. Linner L, Schioler H, Samuelsson E, Milsom I, Nilsson F (2011) Low persistence rates of anticholinergic drug use in Sweden. Eur J Clin Pharmacol 67:535–536

    Article  PubMed  Google Scholar 

  8. Balachandran AA, Duckett JR (2015) The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder. Eur J Obstet Gynecol Reprod Biol 187:60–63

    Article  CAS  PubMed  Google Scholar 

  9. Abrams P, Kelleher C, Staskin D et al (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67:577–588

    Article  CAS  PubMed  Google Scholar 

  10. Yamaguchi O, Kakizaki H, Homma Y et al (2015) Safety and efficacy of mirabegron as “add-on” therapy in patients with overactive bladder treated with solifenacin; a post-marketing, open label study in Japan (MILAI study). BJU Int 116:612–622

    Article  CAS  PubMed  Google Scholar 

  11. Wagg A, Compion G, Fahey A, Suddiqui E (2012) persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Astellas has previous provided funding for the initial assessment of this cohort. However, they provided no funding for this long-term follow-up and have not had access to the manuscript or any results contained therein.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jonathan Duckett.

Ethics declarations

Conflicts of interest

The initial study of 354 patients was supported by a research grant from Astellas. No support was provided for the 1-year follow-up study. Astellas provided no input into the 1-year study.

J. Duckett: see acknowledgements above. A. Balachandran: none.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duckett, J., Balachandran, A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J 27, 1163–1167 (2016). https://doi.org/10.1007/s00192-016-2945-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-016-2945-4

Keywords

Navigation